We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer Applies for EUA for Its Oral COVID-19 Treatment, Inks Deal With Medicines Patent Pool

Pfizer Applies for EUA for Its Oral COVID-19 Treatment, Inks Deal With Medicines Patent Pool

November 17, 2021

Pfizer has filed its application with the FDA for Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, Paxlovid, for the treatment of mild-to-moderate COVID-19 in patients at increased risk of hospitalization or death.

Earlier this month, an interim analysis of a phase 2/3 study showed that the drug cut the risk of COVID-19-associated hospitalizations and death by 89 percent compared to placebo. The study was stopped due to “overwhelming efficacy,” the company said (DID, Nov. 9).

If approved, Paxlovid would be the first oral antiviral of its kind — a 3CL protease inhibitor — that could be prescribed as an at-home treatment to high-risk patients at the first sign of infection, potentially helping patients avoid severe illness.

“We are moving as quickly as possible in our effort to get this potential treatment into the hands of patients, and we look forward to working with the U.S. FDA on its review of our application, along with other regulatory agencies around the world,” said Albert Bourla, chairman and CEO of Pfizer, in a statement.

Paxlovid is hot on the heels of Merck’s and Ridgeback Biotherapeutics’ oral antiviral COVID-19 medication molnupiravir, which got its first green light from a regulatory body in early November when the UK approved it, making it the first oral antiviral medicine authorized for the treatment of COVID-19 (DID, Nov. 5).

Pfizer this week signed an agreement with the Medicines Patent Pool, allowing the pool to make deals with other drugmakers in order to create generic versions of Paxlovid for 95 low- and middle-income countries.

Paxlovid doesn't yet have approval from any regulatory bodies.

Also in the race to get an oral COVID-19 treatment to market is Gilead Sciences, which is developing oral treatments for nonhospitalized patients and hopes to file investigational new drug applications with the FDA by early next year (DID, Sept. 24).  — Suz Redfearn

COVID-19

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • BioVentrix gets Expanded Access Approval for Left Ventricle Support System

  • FDA Approves Stemline’s Orserdu for Several Forms of Breast Cancer

  • FDA Issues Update on LivaNova Recall of Blood Pumping System

  • EU Expands Dupixent’s Authorization to Include Eosinophilic Esophagitis

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing